Literature DB >> 23727027

Disambiguation of PharmGKB drug-disease relations with NDF-RT and SPL.

Qian Zhu1, Robert R Freimuth, Jyotishman Pathak, Matthew J Durski, Christopher G Chute.   

Abstract

PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs. PharmGKB contains information about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations on drug-related phenotypes. These relationships are represented using very general terms, however, and the precise semantic relationships among drugs, and diseases are not often captured. In this paper we develop a protocol to detect and disambiguate general clinical associations between drugs and diseases using more precise annotation terms from other data sources. PharmGKB provides very detailed clinical associations between genetic variants and drug response, including genotype-specific drug dosing guidelines, and this procedure will armGKB. The availability of more detailed data will help investigators to conduct more precise queries, such as finding particular diseases caused or treated by a specific drug. We first mapped drugs extracted from PharmGKB drug-disease relationships to those in the National Drug File Reference Terminology (NDF-RT) and to Structured Product Labels (SPLs). Specifically, we retrieved drug and disease role relationships describing and defining concepts according to their relationships with other concepts from NDF-RT. We also used the NCBO (National Center for Biomedical Ontology) annotator to annotate disease terms from the free text extracted from five SPL sections (indication, contraindication, ADE, precaution, and warning). Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical associations; NDF-RT; PharmGKB; Pharmacogenomics; SPL

Mesh:

Year:  2013        PMID: 23727027      PMCID: PMC3746070          DOI: 10.1016/j.jbi.2013.05.005

Source DB:  PubMed          Journal:  J Biomed Inform        ISSN: 1532-0464            Impact factor:   6.317


  11 in total

Review 1.  Fluorescent dyes for lymphocyte migration and proliferation studies.

Authors:  C R Parish
Journal:  Immunol Cell Biol       Date:  1999-12       Impact factor: 5.126

2.  LOINC, a universal standard for identifying laboratory observations: a 5-year update.

Authors:  Clement J McDonald; Stanley M Huff; Jeffrey G Suico; Gilbert Hill; Dennis Leavelle; Raymond Aller; Arden Forrey; Kathy Mercer; Georges DeMoor; John Hook; Warren Williams; James Case; Pat Maloney
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

3.  ADEpedia: a scalable and standardized knowledge base of Adverse Drug Events using semantic web technology.

Authors:  Guoqian Jiang; Harold R Solbrig; Christopher G Chute
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

4.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

5.  Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.

Authors:  Reijiro Arakawa; Norimasa Tamehiro; Tomoko Nishimaki-Mogami; Kazumitsu Ueda; Shinji Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-24       Impact factor: 8.311

6.  Identifying potential adverse effects using the web: a new approach to medical hypothesis generation.

Authors:  Adrian Benton; Lyle Ungar; Shawndra Hill; Sean Hennessy; Jun Mao; Annie Chung; Charles E Leonard; John H Holmes
Journal:  J Biomed Inform       Date:  2011-07-26       Impact factor: 6.317

Review 7.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

8.  Integrating VA's NDF-RT drug terminology with PharmGKB: preliminary results.

Authors:  Jyotishman Pathak; Laura C Weiss; Matthew J Durski; Qian Zhu; Robert R Freimuth; Christopher G Chute
Journal:  Pac Symp Biocomput       Date:  2012

9.  Extraction of Conditional Probabilities of the Relationships Between Drugs, Diseases, and Genes from PubMed Guided by Relationships in PharmGKB.

Authors:  Martin Theobald; Nigam Shah; Jeff Shrager
Journal:  Summit Transl Bioinform       Date:  2009-03-01

10.  Extending the "web of drug identity" with knowledge extracted from United States product labels.

Authors:  Oktie Hassanzadeh; Qian Zhu; Robert Freimuth; Richard Boyce
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2013-03-18
View more
  4 in total

1.  Evaluation of RxNorm for Medication Clinical Decision Support.

Authors:  Robert R Freimuth; Kelly Wix; Qian Zhu; Mark Siska; Christopher G Chute
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

2.  Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing.

Authors:  Liwei Wang; Hongfang Liu; Christopher G Chute; Qian Zhu
Journal:  BioData Min       Date:  2015-02-25       Impact factor: 2.522

3.  SeBioGraph: Semi-supervised Deep Learning for the Graph via Sustainable Knowledge Transfer.

Authors:  Yugang Ma; Qing Li; Nan Hu; Lili Li
Journal:  Front Neurorobot       Date:  2021-04-01       Impact factor: 2.650

4.  The relative resistance of children to sepsis mortality: from pathways to drug candidates.

Authors:  Rose B Joachim; Gabriel M Altschuler; John N Hutchinson; Hector R Wong; Winston A Hide; Lester Kobzik
Journal:  Mol Syst Biol       Date:  2018-05-17       Impact factor: 11.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.